1. IL-35 over-expression increases apoptosis sensitivity and suppresses cell growth in human cancer cells.
- Author
-
Long J, Zhang X, Wen M, Kong Q, Lv Z, An Y, and Wei XQ
- Subjects
- Apoptosis drug effects, Cell Cycle Checkpoints drug effects, Cell Cycle Checkpoints genetics, Cell Cycle Checkpoints physiology, Cell Line, Tumor, Cyclin D1 biosynthesis, Down-Regulation, Gene Expression Regulation, Neoplastic, Humans, Inhibitor of Apoptosis Proteins biosynthesis, Interferon-gamma pharmacology, Minor Histocompatibility Antigens, Proto-Oncogene Proteins c-bcl-2 biosynthesis, Survivin, Tumor Necrosis Factor-alpha pharmacology, Up-Regulation, fas Receptor biosynthesis, Apoptosis physiology, Cell Proliferation, Interleukin-12 Subunit p35 biosynthesis, Interleukins biosynthesis, Neoplasms metabolism, Neoplasms pathology, Tumor Suppressor Proteins biosynthesis
- Abstract
Interleukin (IL)-35 is a novel heterodimeric cytokine in the IL-12 family and is composed of two subunits: Epstein-Barr virus-induced gene 3 (EBI3) and IL-12p35. IL-35 is expressed in T regulatory (Treg) cells and contributes to the immune suppression function of these cells. In contrast, we found that both IL-35 subunits were expressed concurrently in most human cancer cell lines compared to normal cell lines. In addition, we found that TNF-α and IFN-γ stimulation led to increased IL-35 expression in human cancer cells. Furthermore, over-expression of IL-35 in human cancer cells suppressed cell growth in vitro, induced cell cycle arrest at the G1 phase, and mediated robust apoptosis induced by serum starvation, TNF-α, and IFN-γ stimulation through the up-regulation of Fas and concurrent down-regulation of cyclinD1, survivin, and Bcl-2 expression. In conclusion, our results reveal a novel functional role for IL-35 in suppressing cancer activity, inhibiting cancer cell growth, and increasing the apoptosis sensitivity of human cancer cells through the regulation of genes related to the cell cycle and apoptosis. Thus, this research provides new insights into IL-35 function and presents a possible target for the development of novel cancer therapies., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF